Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Short-term Investments (2022 - 2024)

Atara Biotherapeutics' Short-term Investments history spans 3 years, with the latest figure at $17.5 million for Q4 2024.

  • For Q4 2024, Short-term Investments fell 32.52% year-over-year to $17.5 million; the TTM value through Dec 2024 reached $17.5 million, down 32.52%, while the annual FY2024 figure was $17.5 million, 32.52% down from the prior year.
  • Short-term Investments reached $17.5 million in Q4 2024 per ATRA's latest filing, up from $146000.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $156.7 million in Q1 2023 to a low of $146000.0 in Q1 2022.
  • Average Short-term Investments over 3 years is $30.0 million, with a median of $6.2 million recorded in 2022.
  • Peak YoY movement for Short-term Investments: skyrocketed 107205.48% in 2023, then plummeted 99.86% in 2024.
  • A 3-year view of Short-term Investments shows it stood at $146000.0 in 2022, then soared by 17628.77% to $25.9 million in 2023, then tumbled by 32.52% to $17.5 million in 2024.
  • Per Business Quant, the three most recent readings for ATRA's Short-term Investments are $17.5 million (Q4 2024), $146000.0 (Q3 2024), and $146000.0 (Q2 2024).